# Bundibugyo Ebola outbreak and vaccine response > Developing situation record from CLSTR: https://clstr.news/situations/bundibugyo-ebola-virus-outbreak-and-vaccine-response > Updated: 2026-11-04T17:08:02.000Z. Sources: 36. Developments: 3. Following an outbreak of the Bundibugyo (BDBV) Ebola virus strain in the Democratic Republic of the Congo, with cases also reported in Uganda, Kenya, and Nigeria, the European Medicines Agency (EMA) and the African Medicines Agency (AMA) issued a joint position paper calling for the rapid commencement of clinical trials. The agencies recommended that national regulatory authorities in African countries provide timely approvals and discussed scientific justifications for potentially bypassing certain animal toxicity studies for vaccines using established platforms like mRNA. In response to the emergency, a vaccine development project was initiated with support from the U.S. Biomedical Advanced Research and Development Authority (BARDA). A partnership including SK bioscience, IAVI, Hilleman Laboratories, and IDT Biologika received funding of up to $99 million to develop, manufacture, and clinically evaluate a single-dose vaccine candidate using the recombinant vesicular stomatitis virus (rVSV) platform. SK bioscience is tasked with vaccine scale-up and mass production, while its German subsidiary, IDT Biologika, handles fill-and-finish processes. As of November 4, 2026, the Africa Centres for Disease Control and Prevention reports the outbreak has resulted in over 10,444 confirmed cases and 5,300 deaths, maintaining a fatality rate of more than 50 percent. The World Health Organization (WHO) has approved clinical trials for two new vaccine candidates specifically developed for the Bundibugyo strain: ChAdOx1 BDBV, developed by the University of Oxford and the Serum Institute of India, and Moderna’s mRNA-1469. These trials are being led by the DRC’s National Institute for Biomedical Research, with researchers expecting initial results by early 2027. While the Ervebo vaccine is in use, WHO chief Tedros Adhanom Ghebreyesus noted it is approved for Ebola but not specifically for the Bundibugyo variant, and emphasized that vaccines should not replace immediate measures such as contact tracing, isolation, and safe burial practices. ## Claims - The Ebola outbreak has killed more than 5,300 people. (reported by 17 sources) - There have been 10,444 confirmed Ebola cases. (reported by 16 sources) - The WHO approved clinical trials for two new Ebola vaccine candidates. (reported by 17 sources) - The ChAdOx1 BDBV vaccine was developed by the University of Oxford and the Serum Institute of India. (reported by 17 sources) - The fatality rate of the outbreak is more than 50 percent. (reported by 17 sources) - The DRC’s National Institute for Biomedical Research is leading the vaccine trial. (reported by 17 sources) - The current outbreak is caused by the Bundibugyo virus. (reported by 17 sources) - The total contract value for the vaccine project is up to $99 million. (reported by 8 sources) - The initial confirmed award amount is $36 million. (reported by 8 sources) - The vaccine candidate is a single-dose formulation. (reported by 8 sources) ## Timeline ### 2026-11-04: WHO approves clinical trials for two new Ebola vaccines in DRC The WHO has approved clinical trials for two new Ebola vaccine candidates targeting the Bundibugyo strain in the DRC, amid an outbreak with over 10,000 cases and a fatality rate exceeding 50 percent. 25 sources. https://clstr.news/cluster/who-approves-clinical-trials-for-two-new-ebola-vaccines ### 2026-10-28: SK bioscience to develop Bundibugyo Ebola vaccine with US BARDA support IAVI and partners SK bioscience, Hilleman Laboratories, and IDT Biologika will develop a single-dose Bundibugyo Ebola vaccine following a BARDA contract worth up to $99 million. 9 sources. https://clstr.news/cluster/iavi-receives-36-million-barda-award-for-bundibugyo-virus-vaccine ### 2026-10-25: EMA and AMA call for accelerated Bundibugyo Ebola vaccine trials The EMA and AMA are urging the rapid acceleration of clinical trials for vaccines against the Bundibugyo Ebola strain due to ongoing outbreaks in the DRC, Uganda, Kenya, and Nigeria. 2 sources. https://clstr.news/cluster/ema-and-ama-call-for-accelerated-bundibugyo-ebola-vaccine-trials --- Cite as: Bundibugyo Ebola outbreak and vaccine response. CLSTR, https://clstr.news/situations/bundibugyo-ebola-virus-outbreak-and-vaccine-response